Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Porcine Health Manag ; 8(1): 41, 2022 Oct 03.
Article in English | MEDLINE | ID: mdl-36192816

ABSTRACT

BACKGROUND: Up to now, information on the levels of maternally-derived antibodies (MDA) against PCV-2 in suckling piglets born to sows vaccinated with different strategies is scarce in the literature. In the present observational study, the PCV-2-specific MDA titres from piglets from 109 farms (thirty 3-day-old and thirty 21-day-old piglets per farm) across four different European countries (France n = 30, Germany n = 27, Italy n = 22 and Spain n = 30) using different sow vaccination strategies (during gestation, as a gilt, as a piglet or never) were assessed. RESULTS: In all four countries, mean log PCV-2 MDA titres were higher in 3-day-old piglets than in the 3-week-old ones, being significant in most of all the comparisons performed. Within each country, the highest PCV-2-specific MDA titres were observed in the 3-day-old piglets born to sows vaccinated during gestation. Indeed, in the four countries, more than 60% of this subpopulation (3-day-old piglets from sows vaccinated during pregnancy) had the highest log PCV-2 titres detectable with the ELISA technique used in this study. The lowest MDA titres were more variable. Whereas in France and Germany the lowest titres corresponded to 21-day-old piglets born from sows vaccinated as a piglet, in Italy, they corresponded to 21-day-old piglets derived from sows vaccinated as a gilt and in Spain to 21-day-old piglets born from non-vaccinated sows. In this study, PCV-2-specific MDA titres at 3 and 21 days of age were not affected by sow parity. CONCLUSIONS: Data obtained could be considered as a European global overview of PCV-2-specific MDA titres present in the pre-vaccinated piglet populations in different European countries, with titres tending to be higher in younger piglets, but with values variable among countries and sow vaccination strategies.

2.
Mucosal Immunol ; 9(3): 689-701, 2016 05.
Article in English | MEDLINE | ID: mdl-26376366

ABSTRACT

Current therapies to treat inflammatory bowel diseases have limited efficacy, significant side effects, and often wane over time. Little is known about the cellular and molecular mechanisms operative in the process of mucosal healing from colitis. To study such events, we developed a new model of reversible colitis in which adoptive transfer of CD4(+)CD45RB(hi) T cells into Helicobacter typhlonius-colonized lymphopenic mice resulted in a rapid onset of colonic inflammation that was reversible through depletion of colitogenic T cells. Remission was associated with an improved clinical and histopathological score, reduced immune cell infiltration to the intestinal mucosa, altered intestinal gene expression profiles, regeneration of the colonic mucus layer, and the restoration of epithelial barrier integrity. Notably, colitogenic T cells were not only critical for induction of colitis but also for maintenance of disease. Depletion of colitogenic T cells resulted in a rapid drop in tumor necrosis factor α (TNFα) levels associated with reduced infiltration of inflammatory immune cells to sites of inflammation. Although neutralization of TNFα prevented the onset of colitis, anti-TNFα treatment of mice with established disease failed to resolve colonic inflammation. Collectively, this new model of reversible colitis provides an important research tool to study the dynamics of mucosal healing in chronic intestinal remitting-relapsing disorders.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Colitis/immunology , Helicobacter Infections/immunology , Inflammatory Bowel Diseases/immunology , Intestinal Mucosa/physiology , Adoptive Transfer , Animals , CD4-Positive T-Lymphocytes/transplantation , Cell Movement , Cells, Cultured , Disease Models, Animal , Gene Expression Regulation , Humans , Intestinal Mucosa/pathology , Lymphocyte Depletion , Mice , Mice, Inbred C57BL , Mice, Knockout , Tumor Necrosis Factor-alpha/metabolism , Wound Healing
3.
J Phys Chem A ; 110(47): 12728-33, 2006 Nov 30.
Article in English | MEDLINE | ID: mdl-17125285

ABSTRACT

Thin MALDI samples can perform differently than thicker samples, on metal substrates. Divergent results and models for the effect have been presented. Positive and negative yields are investigated here for three matrixes (2,5-dihydroxybenzoic acid (DHB), sinapinic acid, and alpha-cyano 4-hydroxycinnamic acid) on stainless steel and gold substrates. Samples were electrosprayed for uniformity and thickness control and imaged across a metal-metal boundary. Thin sample enhancement is found in both polarities for all three matrixes on a steel substrate. On gold, only alpha-cyano-4-hydroxycinnamic acid shows enhancement. These and earlier data are used to evaluate two models. The first is based on one-photon photoelectron emission from the metal; the second one, on two-photon matrix ionization at the metal interface. The surface-enhanced matrix photoionization model best fits the evidence, including the fluence dependence of electron emission from DHB on steel.


Subject(s)
Gold/chemistry , Models, Chemical , Particle Size , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Stainless Steel/chemistry , Coumaric Acids/chemistry , Gentisates/chemistry , Ions , Models, Molecular , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/instrumentation
4.
J Cancer Res Clin Oncol ; 126(11): 647-54, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11079729

ABSTRACT

In the search for new anti-breast cancer compounds a series of diastereomeric aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine]sulfato platinum(II) complexes was tested on the hormone-sensitive MXT-M-3.2 breast cancer of the mouse. By simultaneous determination of tumor and uterine weights at the end of the experiment we obtained an insight into the mode of action. Changes in the uterine weights indicate whether the anti-breast cancer effect of the test substance is caused either by its capability to reduce the endogenous estrogen level via inhibition of estrogen biosynthesis (mechanism B), or by its estrogenic side effects which enhance the immune defense in the host animals (mechanism C). Studies on the [3H]thymidine incorporation into DNA of MDAMB-231 breast cancer cells showed that all test compounds inhibit deoxyribonucleic acid synthesis, like cisplatin (mechanism A). However, in comparison to the standard cisplatin, their activities were low. The three most effective test compounds threo-2-PtSO4 (2-phenyl-residue), threo-5-PtSO4 (2-(4-hydroxyphenyl)-residue), and threo-8-PtSO4 (2-(2-fluoro-4-hydroxyphenyl)-residue) seem to exert their anti-breast cancer effect by mechanism B. Moreover, threo-5-PtSO4 was moderately active on the hormone- insensitive MXT-M-3.2 (Ovex) breast cancer of the mouse. Aqua[erythro-1-(2,6-dichloro-4-hydroxyphenyl)-2-(2-chloro-4-hydroxypheny l) ethylenediamine]sulfato-platinum(II) (erythro-9-PtSO4) was the only breast cancer inhibiting compound of the series acting mainly according to mechanism C. A minor contribution of mechanism A, impairment of the DNA function in the tumor cell, to the anti-breast cancer activity of these aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine]sulfato platinum(II) complexes cannot be excluded, since such effects are apparent in the MDA-MB-231 as well as in the MCF-7 breast cancer cell line at higher drug concentrations. In this test series which was performed with the crystal violet chemosensitivity assay, the MCF-7 cells proved to be somewhat more sensitive.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Organoplatinum Compounds/pharmacology , Animals , Breast Neoplasms/metabolism , DNA, Neoplasm/biosynthesis , Drug Screening Assays, Antitumor , Female , Humans , Mammary Neoplasms, Experimental/drug therapy , Mice , Neoplasm Transplantation , Neoplasms, Hormone-Dependent/drug therapy , Receptors, Estrogen/physiology , Structure-Activity Relationship , Tumor Cells, Cultured
5.
Arch Pharm (Weinheim) ; 328(5): 457-63, 1995 May.
Article in English | MEDLINE | ID: mdl-7611841

ABSTRACT

[1,2-Bis(4-methoxy/4-hydroxyphenyl)ethylenediamine]dichloroplatinum-(II) complexes with Cl-, CH3-, or OCH3-substituents in the ortho-positions of the aromatic rings (meso-1-PtCl2, D,L-1-PtCl2, meso-2-PtCl2, D,L-2-PtCl2, meso-3-PtCl2, meso-4-PtCl2, meso-5-PtCl2) were tested on the MDA-MB 231 breast cancer cell line, the lymphocytic leukemia P388, and the estrogen receptor-positive and -negative MXT mammary carcinoma of the mouse (MXT,ER(+)-MC, MXT,ER(-)-MC). The comparison of the effects of methoxy-substituted complexes (meso-1-PtCl2, D,L-1-PtCl2, meso-3-PtCl2) with those of the respective hydroxy-substituted ones (meso-2-PtCl2, D,L-2-PtCl2, meso-4-PtCl2) shows that a reduction of estrogenic effects as well as a total loss of the mammary tumor-inhibiting activity takes place on methylation of the 4-OH group. The exchange of the 2,6-standing chlorine atoms by methyl groups in meso-2-PtCl2 led to the non-estrogenic, but on the MXT,ER(+)-MC highly effective derivative meso-4-PtCl2 which proved to be also cytotoxic on ER(-)-tumors such as MXT,ER(-)-MC, and the P388 leukemia.


Subject(s)
Antineoplastic Agents/pharmacology , Estradiol Congeners/pharmacology , Organoplatinum Compounds/chemical synthesis , Animals , Antineoplastic Agents/chemistry , Breast Neoplasms/drug therapy , Estradiol Congeners/chemistry , Female , Humans , Magnetic Resonance Spectroscopy , Mice , Mice, Inbred DBA , Organoplatinum Compounds/chemistry , Rats , Rats, Sprague-Dawley , Receptors, Estrogen/drug effects , Receptors, Estrogen/metabolism , Structure-Activity Relationship , Tumor Cells, Cultured
6.
Cancer Res ; 51(12): 3217-23, 1991 Jun 15.
Article in English | MEDLINE | ID: mdl-2039997

ABSTRACT

The Pt complex [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)-ethylenediamine]diaqua -Pt(II) sulfate (meso-6-PtSO4) was designed with the concept of combining the cytotoxic cisplatin with an estrogen receptor (ER)-binding ligand for targeting to ER+ mammary tumor cells. This Pt complex selectively inhibits growth of ER+ mammary tumors in rodents. To study the cellular mechanisms of action, cultures of two human mammary tumor cell lines, MCF-7 (ER+) and MDA-MB231 (ER-), were used and the effects of estradiol, tamoxifen, and cis-Pt compared with those of meso-6-PtSO4. The relative binding affinity of the meso-6-PtSO4 to the ER in MCF-7 cells was 0.35 compared to estradiol (relative binding affinity, 100). Nevertheless, the Pt complex was able to induce ER processing and increase the level of the progesterone receptor at concentrations of 1-10 nM. Growth of MCF-7 cells was inhibited at concentrations of meso-6-PtSO4 greater than 10 microM. MDA-MB231 cells were inhibited likewise by the Pt complex, indicating a lack of selectivity for the ER+ cells. The results show that meso-6-PtSO4 possesses both estrogen-like and cis-Pt-like properties. Since growth inhibition did not correlate with ER-mediated processes, these two properties are expressed independently at the cellular level. The selective growth inhibitory effect of meso-6-PtSO4 in vivo is suggested to involve endocrinological and/or immunological factors.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Survival/drug effects , Organoplatinum Compounds/pharmacology , Receptors, Estrogen/metabolism , Receptors, Progesterone/biosynthesis , Breast Neoplasms , Cell Division/drug effects , Cell Line , Dose-Response Relationship, Drug , Estradiol/pharmacology , Female , Humans , Kinetics , Receptors, Progesterone/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...